Recess key facts
as of Oct 2026- Producer of sparkling beverages intended to offer a calm and balanced drinking experience.
- Recess is valued at approximately $156.9M as of Oct 2026, per PrivateMarketView’s mark.
- It has raised $84.5M; the latest was Later Stage VC ($45.6M) in Dec 2025.
- Notable investors include Gaingels, Evolution VC Partners, Great Oaks Venture Capital, Riverside Ventures, Siddhi Capital — 28 tracked in total.
- 1 institutional filer reports fund marks on Recess across 6 filings.
- Status: Privately Held (backing).
- ·The complete investor list: 28 names
- ·Watch Recess: the Monday email on marks, rounds and moves
Institutional fund marks on Recess
1 filers · latest Jul 20261 SEC-registered fund reported 6 fair-value marks on Recess between Apr 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
Recess funding rounds
No funding rounds for Recess are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Recess
28+Recess valuation
Recess is valued at approximately $157 million as of Oct 2026. The figure is set by institutional fund marks.
Recent activity
In the last 90 days, Recess's record added 1 institutional fund mark (latest period Jul 2026).
Institutional holders and vehicles
1 SEC-registered fund reported 6 fair-value marks on Recess between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Recess investors
28 investors are on record for Recess, including Gaingels, Evolution VC Partners, Great Oaks Venture Capital and Riverside Ventures. By type, the record holds 6 venture capital firms and 2 growth equity firms.
About Recess
Producer of sparkling beverages intended to offer a calm and balanced drinking experience. The company's beverages are infused with powerful natural ingredients, hemp herb extracts, and adaptogens that boost immunity and replenish the body's endocannabinoid system, enabling consumers to improve their mental performance by increasing concentration, attention, and thinking speed.
- Sector
- Consumer Products and Services (B2C)
- HQ
- New York, NY, United States
- Founded
- 2018
- Employees
- 45
- Website
- takearecess.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.